Structural Formula Rocuronium Bromide (Rocuronium 01)
Rocuronium Bromide Injection, Solution
Product Images NDC 0409-9558
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 0409-9558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Time To 80% Or Greater Block Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium 02)
Figure 2: Duration Of Clinical Effect Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium 03)
This is a figure showing the duration of clinical effect versus the initial dose of Rocuronium Bromide categorized by age group. The values are presented in minutes, along with the median, 25th, and 75th percentile, and individual values. The age groups represented are 18-64 years, greater than or equal to 65 years, 3 months - 1 year old, and 1-12 years old. However, no explanation is provided about the results or what the figure represents, making it difficult to fully understand the data.*
Figure 3: Duration Of Clinical Effect Vs. Number Of Rocuronium Bromide Maintenance Doses, By Dose (Rocuronium 04)
Hospira Logo (Rocuronium 05)
Principal Display Panel (5 mL Vial Label)
This is a warning label for a multiple-dose vial of Rocuronium Bromide Injection, a paralyzing agent used for intravenous use only. The vial contains 50 mg/5 mL (10 mg/mL) rocuronium bromide which can cause respiratory arrest, and the facilities for artificial respiration must be immediately available. Read the enclosed prescribing information for dosage instructions. The injection is sterile and nonpyrogenic and should be stored under refrigeration maintaining a temperature between 2 to 8°C (36 to 46°F). Do not freeze or use beyond 30 days after opening, as stated in the expiration date.*
Principal Display Panel (5 mL Vial Box)
This is a product description for Rocuronium Bromide Injection, which is supplied in 50 mg/5 mL (10 mg/mL) concentration in a 10 x 5 mL multiple dose vials package. The injection should be stored at refrigeration temperature (2 to °C) and should not be frozen. The product should be used only for intravenous use and contains a warning as it could paralyze respiratory function. The injection is sterile, nonpyrogenic, and contains 10mg rocuronium bromide with 2 ma sodium acetate. The pH of the injection is adjusted with acetic acid and/or NaOH. The packaging contains a warning about potential respiratory depression and the need for immediate availability of facilities for artificial respiration. This product is distributed by Hospira, Inc., Lake Forest, IL 60045 USA, and contains the GTIN 10304099558051.*
Principal Display Panel (10 mL Vial Label)
This is a description of a drug named Rocuronium Bromide Injection. The drug is a paralyzing agent used for intravenous use only. It comes in a 10 mL multiple-dose vial with a 100mg/10mL (10mg/mL) concentration. The drug requires immediate medical attention as it may cause respiratory arrest. The dosage depends on the enclosed prescribing information. The drug is sterile, nonpyrogenic, and each mL contains 10mg rocuroniumbromide, 2mg sodium acotate. The drug is adjusted to isotonicity with 3.1mg/mL NaCl and a pH of 4 with acetic acid and/or NaOH. It has to be stored under refrigeration at 2-8°C (36 to
46°F), and the opened vials should be used within 60 days.*
Principal Display Panel (10 mL Vial Box)
This is a drug product named "Rocuronium Bromide Injection," which comes in the form of 10 x 10 mL multiple dose vials. Each mL of the injection contains 10 mg of rocuronium bromide, and it is intended for intravenous use only. The product should be stored under refrigeration at 2 to 8°C and should not be frozen. Upon removal from refrigeration, it should be used within 60 days at room temperature, or opened vials should be used within 30 days. The injection is sterile and non-pyrogenic, and it is adjusted to isotonicity with 3.1 g/l NaCl and to a pH of 4 with acetic acid and/or NaOH. However, the product has a warning that it is a Paralyzing Agent and may cause Respiratory Arrest. Therefore, facilities must have respiratory support immediately available. Lastly, the drug is distributed by Hospira, Inc., and the NDC code is 0409-9558-10.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
